BK0579 Biomedical
- 783.251
- +7.192+0.93%
Additional Considerations Required While Assessing Nanning Department Store's (SHSE:600712) Strong Earnings
Nanning Department Store Co., Ltd. (SHSE:600712) just reported some strong earnings, and the market reacted accordingly with a healthy uplift in the share price. However, we think that shareholders m
Huasun Technology to Cancel 3.8 Million Repurchased Shares
Chinese drugmaker Chengdu Huasun Technology Group (SHE:000790) will cancel 3.8 million shares that the company repurchased, the company said in its filing on the Shenzhen Stock Exchange. The shares, w
Returns On Capital At Hangzhou First Applied Material (SHSE:603806) Have Stalled
If we want to find a stock that could multiply over the long term, what are the underlying trends we should look for? Firstly, we'll want to see a proven return on capital employed (ROCE) that is inc
Jiangsu Jibeier Pharmaceutical (SHSE:688566) Posted Healthy Earnings But There Are Some Other Factors To Be Aware Of
Jiangsu Jibeier Pharmaceutical Co., Ltd.'s (SHSE:688566) robust earnings report didn't manage to move the market for its stock. Our analysis suggests that shareholders have noticed something concerni
Yabao Pharmaceutical Group's (SHSE:600351) Performance Is Even Better Than Its Earnings Suggest
Even though Yabao Pharmaceutical Group Co., Ltd's (SHSE:600351) recent earnings release was robust, the market didn't seem to notice. We think that investors have missed some encouraging factors unde
We Think You Should Be Aware Of Some Concerning Factors In ChengDu ShengNuo BiotecLtd's (SHSE:688117) Earnings
The market for ChengDu ShengNuo Biotec Co.,Ltd.'s (SHSE:688117) stock was strong after it released a healthy earnings report last week. While the profit numbers were good, our analysis has found some
North China Pharmaceutical Company.Ltd (SHSE:600812) Strong Profits May Be Masking Some Underlying Issues
North China Pharmaceutical Company.Ltd (SHSE:600812) just released a solid earnings report, and the stock displayed some strength. Despite this, our analysis suggests that there are some factors weak
Huahai Pharmaceutical's Q1 Profit Jumps 57%, Income Up 21%
Zhejiang Huahai Pharmaceutical (SHA:600521) booked a net profit attributable to shareholders of 270.8 million yuan in the first quarter of the year, jumping 56.6% from 172.9 million yuan a year earlie
The Hang Seng Index rose more than 2%, the Hang Seng Technology Index rose 3.7%, Hong Kong biotech stocks rose higher, Cansino Biotech rose more than 10%, and Rongchang Biotech rose more than 6%.
The Hang Seng Index rose more than 2%, the Hang Seng Technology Index rose 3.7%, Hong Kong biotech stocks rose higher, Cansino Biotech rose more than 10%, and Rongchang Biotech rose more than 6%.
We Think Beijing Kawin Technology Share-Holding (SHSE:688687) Can Stay On Top Of Its Debt
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the permanent loss of capital.' It's only natural to consider a company's balance sheet wh
Zhejiang Jiuzhou Pharmaceutical's (SHSE:603456) Profits May Not Reveal Underlying Issues
The market for Zhejiang Jiuzhou Pharmaceutical Co., Ltd's (SHSE:603456) stock was strong after it released a healthy earnings report last week. However, we think that shareholders should be cautious
We Think That There Are Issues Underlying Gan & Lee Pharmaceuticals' (SHSE:603087) Earnings
Gan & Lee Pharmaceuticals.'s (SHSE:603087) robust earnings report didn't manage to move the market for its stock. We did some digging, and we found some concerning factors in the details. SHSE:603
Is Qingdao Hiron Commercial Cold Chain Co., Ltd. (SHSE:603187) Trading At A 50% Discount?
Key Insights The projected fair value for Qingdao Hiron Commercial Cold Chain is CN¥27.78 based on 2 Stage Free Cash Flow to Equity Qingdao Hiron Commercial Cold Chain's CN¥14.00 share price signals
Frontier Biology (688221) Quarterly Report Review: The year-on-year sales growth rate of innovative domestic HIV drugs is impressive, and deep academic accumulation helps promote products
Incidents. The company announced its 2024 quarterly report. In Q1 2024, the company achieved sales revenue of 24.65 million yuan, a year-on-year increase of 106.93%, net profit attributable to mother - 55.71 million yuan, net profit from non-return to mother - 62.69 million yuan
Cotobiotics (300858): Probiotics business performed well in 2023, increasing revenue share to 64%
Profit for 2023 and 1Q24 is in line with market expectations of $299 million, or -18.94% year-on-year; net profit to mother was $93 million, or -14.93% year-on-year. 1Q24 operating income 0.5
Hualan Biology (002007): The Q1 blood products business remains steady and we expect the influenza vaccine to be released
Core view On April 25, the company released its 2024 quarterly report. The year-on-year decline in performance was mainly due to a high sales base for influenza vaccines, and the blood products business maintained steady growth. In terms of blood products, it is expected that as the amount of pulp collected continues to increase, it will be superimposed
Bipli Pharmaceuticals (300630.SZ) has not completed its self-inspection of the previous report and is unable to disclose the regular report on schedule. Stock and bond trading was suspended from May 6
Puri Pharmaceuticals (300630.SZ) issued an announcement that the company was unable to meet the legal deadline (April 30, 2024...
Zhixiang Jintai (688443): Celizumab approved soon, multiple assets are in the advanced clinical phase
The 2023 results are in line with our expectations. The company announced its 2023 results: net profit to mother - 801 million yuan, mainly due to multiple innovative drug assets to advance the post-clinical phase. Expenses are high, and the company's 23-year performance is in line with our expectations.
Dizhe Pharmaceutical (688192): Revenue is in line with expectations, core products are progressing in an orderly manner worldwide
The 2023 and 1Q24 results are in line with our expectations. The company announced the 2023 and 1Q24 results: 2023 revenue of 91.289 million yuan, net profit to mother of 1.11 billion yuan, in line with our expectations. incorporation
Zhejiang Starry Pharmaceutical Co.,Ltd.'s (SHSE:603520) 10.0% Gain Last Week Benefited Both Retail Investors Who Own 48% as Well as Insiders
Key Insights Zhejiang Starry PharmaceuticalLtd's significant retail investors ownership suggests that the key decisions are influenced by shareholders from the larger public The top 15 shareholders